Compare Stocks: ACIU, SANA, JANX, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.22 +1.4%	$2.40	$2.03 ▼ $4.00	$222.88M	1.59	196,042 shs	118,333 shs
JANX Janux Therapeutics	$15.32 +1.0%	$14.93	$12.12 ▼ $35.34	$925.13M	2.5	841,800 shs	558,942 shs
PHAR Pharming Group	$9.82 -2.6%	$12.97	$9.62 ▼ $21.34	$713.44M	-0.01	9,228 shs	33,875 shs
SANA Sana Biotechnology	$3.18 +1.6%	$3.28	$2.61 ▼ $6.55	$871.05M	2.16	2.68 million shs	2.49 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+1.37%	-3.48%	-11.55%	-26.25%	+4.72%
JANX Janux Therapeutics	+0.99%	-1.61%	-1.42%	+6.91%	-34.97%
PHAR Pharming Group	-2.58%	-23.01%	-28.69%	-39.27%	-10.40%
SANA Sana Biotechnology	+1.60%	-3.05%	-20.70%	-8.88%	-18.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.22 +1.4%	$2.40	$2.03 ▼ $4.00	$222.88M	1.59	196,042 shs	118,333 shs
JANX Janux Therapeutics	$15.32 +1.0%	$14.93	$12.12 ▼ $35.34	$925.13M	2.5	841,800 shs	558,942 shs
PHAR Pharming Group	$9.82 -2.6%	$12.97	$9.62 ▼ $21.34	$713.44M	-0.01	9,228 shs	33,875 shs
SANA Sana Biotechnology	$3.18 +1.6%	$3.28	$2.61 ▼ $6.55	$871.05M	2.16	2.68 million shs	2.49 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+1.37%	-3.48%	-11.55%	-26.25%	+4.72%
JANX Janux Therapeutics	+0.99%	-1.61%	-1.42%	+6.91%	-34.97%
PHAR Pharming Group	-2.58%	-23.01%	-28.69%	-39.27%	-10.40%
SANA Sana Biotechnology	+1.60%	-3.05%	-20.70%	-8.88%	-18.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.40	Hold	$7.50	237.84% Upside
JANX Janux Therapeutics	2.50	Moderate Buy	$38.08	148.59% Upside
PHAR Pharming Group	2.40	Hold	$38.67	293.75% Upside
SANA Sana Biotechnology	2.67	Moderate Buy	$9.50	198.74% Upside

Current Analyst Ratings Breakdown

Latest ACIU, SANA, JANX, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/25/2026	JANX Janux Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $26.00
5/11/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
5/11/2026	JANX Janux Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$22.00
5/11/2026	SANA Sana Biotechnology	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$16.00
5/8/2026	ACIU AC Immune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/8/2026	JANX Janux Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$30.00 ➝ $26.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$4.31M	52.42	N/A	N/A	$0.54 per share	4.11
JANX Janux Therapeutics	$10M	93.42	N/A	N/A	$15.91 per share	0.96
PHAR Pharming Group	$376.13M	1.85	$0.20 per share	50.26	$3.95 per share	2.49
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.82	N/A	13.06	N/A	-1,788.02%	-125.26%	-40.85%	8/4/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.84	N/A	N/A	N/A	N/A	-12.93%	-12.23%	8/6/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	81.83	19.64	N/A	2.51%	3.40%	1.88%	N/A
SANA Sana Biotechnology	-$244.17M	-$0.93	N/A	N/A	N/A	N/A	-108.01%	-40.68%	8/10/2026 (Estimated)

Latest ACIU, SANA, JANX, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.26	N/A	N/A	N/A	$19.08 million	N/A
8/4/2026	Q2 2026	ACIU AC Immune	$0.1214	N/A	N/A	N/A	$34.08 million	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	$90.20 million
5/11/2026	Q1 2026	SANA Sana Biotechnology	-$0.15	-$0.14	+$0.01	-$0.17	N/A	N/A
5/7/2026	Q1 2026	JANX Janux Therapeutics	-$0.5202	-$0.39	+$0.1302	-$0.39	$4.36 million	$3.73 million
5/7/2026	Q1 2026	PHAR Pharming Group	$0.05	-$0.07	-$0.12	-$0.07	$92.06 million	$72.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.87	1.02
JANX Janux Therapeutics	N/A	17.01	17.01
PHAR Pharming Group	0.35	2.63	2.06
SANA Sana Biotechnology	N/A	1.29	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
JANX Janux Therapeutics	75.39%
PHAR Pharming Group	0.03%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
JANX Janux Therapeutics	7.90%
PHAR Pharming Group	2.07%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	101.77 million	97.09 million	Optionable
JANX Janux Therapeutics	30	60.98 million	56.17 million	Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable
SANA Sana Biotechnology	380	278.29 million	207.61 million	Optionable

ACIU, SANA, JANX, and PHAR Headlines

Recent News About These Companies

Sana Biotechnology (SANA) Projected to Release Earnings on Monday

August 3 at 9:55 AM | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of "Moderate Buy" by Analysts

August 1 at 3:15 AM | americanbankingnews.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

July 29, 2026 | prnewswire.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 6.8% - Should You Buy?

July 27, 2026 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages

July 27, 2026 | marketbeat.com

Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold

July 25, 2026 | seekingalpha.com

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

July 22, 2026 | seekingalpha.com

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

July 20, 2026 | zacks.com

Sana Biotechnology (NASDAQ:SANA) Rating Lowered to "Sell" at Wall Street Zen

July 20, 2026 | marketbeat.com

Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM

July 16, 2026 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 11.1% - Here's Why

July 16, 2026 | marketbeat.com

Sana (SANA) Upgraded to Buy: Here's What You Should Know

July 15, 2026 | zacks.com

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune ...

July 13, 2026 | markets.businessinsider.com

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

July 13, 2026 | globenewswire.com

Sana Biotechnology (NASDAQ:SANA) Upgraded to "Hold" at Wall Street Zen

July 12, 2026 | marketbeat.com

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

July 1, 2026 | globenewswire.com

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

June 12, 2026 | finance.yahoo.com

As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?

June 10, 2026 | msn.com

Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Sana Biotechnology Shareholders Reelect Directors and Ratify Auditor

June 5, 2026 | tipranks.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

June 2, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACIU, SANA, JANX, and PHAR Company Descriptions

AC Immune NASDAQ:ACIU

$2.22 +0.03 (+1.37%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$2.27 +0.05 (+2.30%)

As of 08/3/2026 07:34 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Janux Therapeutics NASDAQ:JANX

$15.32 +0.15 (+0.99%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$15.31 -0.01 (-0.06%)

As of 08/3/2026 07:37 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Pharming Group NASDAQ:PHAR

$9.82 -0.26 (-2.58%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$10.16 +0.34 (+3.47%)

As of 04:10 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Sana Biotechnology NASDAQ:SANA

$3.18 +0.05 (+1.60%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$3.18 -0.01 (-0.16%)

As of 04:13 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACIU, SANA, JANX, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACIU, SANA, JANX, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACIU, SANA, JANX, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACIU, SANA, JANX, and PHAR Company Descriptions

AC Immune NASDAQ:ACIU

Janux Therapeutics NASDAQ:JANX

Pharming Group NASDAQ:PHAR

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACIU, SANA, JANX, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACIU, SANA, JANX, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACIU, SANA, JANX, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACIU, SANA, JANX, and PHAR Company Descriptions

AC Immune NASDAQ:ACIU

Janux Therapeutics NASDAQ:JANX

Pharming Group NASDAQ:PHAR

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools